TPMT, 1_245aa, Human, Recombinant, E.coli
- Known as:
- TPMT, 1_245aa, Human, Recombinant, E.coli
- Catalog number:
- TPM0701
- Product Quantity:
- 0.5mg
- Category:
- -
- Supplier:
- ATGen
- Gene target:
- TPMT 1_245aa Human Recombinant .coli
Related genes to: TPMT, 1_245aa, Human, Recombinant, E.coli
- Gene:
- FCN2 NIH gene
- Name:
- ficolin 2
- Previous symbol:
- -
- Synonyms:
- P35, FCNL, EBP-37, ficolin-2
- Chromosome:
- 9q34.3
- Locus Type:
- gene with protein product
- Date approved:
- 1996-07-11
- Date modifiied:
- 2016-10-05
- Gene:
- TPMT NIH gene
- Name:
- thiopurine S-methyltransferase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-08-25
- Date modifiied:
- 2019-04-23
Related products to: TPMT, 1_245aa, Human, Recombinant, E.coli
Related articles to: TPMT, 1_245aa, Human, Recombinant, E.coli
- Interindividual variability in the efficacy and toxicity of 6-mercaptopurine (6-MP) and methotrexate (MTX) drugs remains a major challenge in the treatment of pediatric acute lymphoblastic leukemia (ALL). Germline variation in pharmacogenes involved in drug metabolism, transport, and folate pathways may contribute to this variability. - Source: PubMed
Publication date: 2026/05/21
Curic IsidoraKotur NikolaRistivojevic BojanPavlovic DjordjeJelovac MarinaKrstajic KatarinaRadosevic MiaDjordjevic AnaPavlovic SonjaRoganovic JelenaZukic Branka - Thiopurine methyltransferase (TPMT) is responsible for the inactivation of azathioprine, and is widely used to treat cutaneous autoimmune diseases. TPMT activity is inherited as an autosomal codominant trait and ranges from high to undetectable levels in different individuals. Low TPMT activity may result in a higher risk of adverse effects (AEs), whereas high TPMT activity may result in potential treatment failure. - Source: PubMed
Publication date: 2026/05/01
Pureesrisak PuritKwangsukstid OrayaKattipathanapong PinnareeKootiratrakarn TanawattSukasem ChonlaphatMairiang DumrongChannakorn WenikaPhainupong DarakaSuphannaphong Mingkwan - - Source: PubMed
Publication date: 2026/04/28
- Thiopurines remain key immunomodulators for inflammatory bowel disease (IBD) but require close safety monitoring for adverse effects. - Source: PubMed
Publication date: 2026/04/25
Ea VinnyFraser JacquelineMitropoulos AlexanderShrestha AtulRodda SheridanBurns MeganBell SallyMoore GregoryGoldberg Rimma - Whole genome sequencing (WGS) is increasingly accessible in clinical practice, enabling pharmacogenomics (PGx) integration, including in pediatric oncology. However, the lack of validated software to accurately annotate clinically actionable PGx variants from WGS limits routine implementation. We therefore aimed to identify and validate a PGx annotation tool suitable for clinical use in pediatric oncology. We evaluated several tools for technical performance and clinical integration. The Pharmacogenomics Clinical Annotation Tool (PharmCAT) was selected for its alignment with expert-reviewed PGx guidelines, inclusion of relevant gene-drug pairs and prescribing recommendations. PharmCAT was validated using an in silico dataset by introducing known diplotypes into the Genome in a Bottle (GIAB) reference sample, complemented by four clinically confirmed diplotypes from three patients. Diplotype and phenotype outputs from WGS were compared against the GIAB and patient reference data. We tested 71 diplotypes across seven genes (TPMT, NUDT15, CYP3A5, CYP2C9, CYP2C19, DPYD, UGT1A1), using ≥ 95% sensitivity and specificity as validation criteria. CYP2D6 was excluded from this validation due to genotyping limitations from the input data used by PharmCAT. The tool was integrated into our WGS analysis pipeline using containerization for consistent, reproducible execution. Diplotype and phenotype results from PharmCAT fully matched the in silico GIAB set and patient samples, achieving 100% sensitivity and specificity. These findings confirm PharmCAT as a reliable tool for preemptive PGx annotation, supporting implementation in pediatric oncology. Its clinical integration supports individualized dosing, reducing adverse effects and improving efficacy. Further validation of additional gene-drug pairs will broaden its clinical utility. - Source: PubMed
Diekstra Meta H MBiesot NienkeDonders JulieVerwiel Eugène T PJanse AlexHuitema Alwin D RHanff Lidwien MTops Bastiaan B JKemmeren PatrickHehir-Kwa Jayne Y